Mylosar
Mylosar Brand names, Mylosar Analogs
Mylosar Brand Names Mixture
- No information avaliable
Mylosar Chemical_Formula
C8H12N4O5
Mylosar RX_link
http://www.rxlist.com/cgi/generic3/vidaza.htm
Mylosar fda sheet
Mylosar msds (material safety sheet)
Mylosar Synthesis Reference
No information avaliable
Mylosar Molecular Weight
244.205 g/mol
Mylosar Melting Point
229 oC
Mylosar H2O Solubility
8.9E+004 mg/L
Mylosar State
Solid
Mylosar LogP
-3.017
Mylosar Dosage Forms
Azacitidine for injectable suspension is supplied as a lyophilized powder in 100 mg single-use vials packaged in cartons of 1 vial.
Mylosar Indication
For treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
Mylosar Pharmacology
Azacitidine is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. Non-proliferating cells are relatively insensitive to azacitidine.
Mylosar Absorption
Azacitidine is rapidly absorbed after subcutaneous administration. The bioavailability of subcutaneous azacitidine relative to IV azacitidine is approximately 89%, based on area under the curve.
Mylosar side effects and Toxicity
One case of overdose with azacitidine was reported during clinical trials. A patient experienced diarrhea, nausea, and vomiting after receiving a single IV dose of approximately 290 mg/m2, almost 4 times the recommended starting dose.
Mylosar Patient Information
Mylosar Organisms Affected
Humans and other mammals
